Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Southeast Asia has been experiencing significant growth in recent years.
Customer preferences: Customers in Southeast Asia have been increasingly concerned about preventing and treating viral infections, leading to a growing demand for antiviral drugs. This trend is driven by several factors, including the increasing prevalence of viral diseases in the region, rising healthcare awareness, and the availability of new and improved antiviral drugs.
Trends in the market: Several countries in Southeast Asia, such as Indonesia, Thailand, and Vietnam, have been investing heavily in their healthcare infrastructure, which has led to an increase in demand for antiviral drugs. In addition, the COVID-19 pandemic has further accelerated the demand for antiviral drugs in the region, with many countries stockpiling these drugs to prepare for future outbreaks.
Local special circumstances: One of the unique challenges facing the antiviral drug market in Southeast Asia is the prevalence of counterfeit drugs. This is particularly problematic in countries with weaker regulatory frameworks, such as Indonesia and the Philippines. To combat this, several governments in the region have implemented stricter regulations and increased enforcement efforts.
Underlying macroeconomic factors: The economic growth in Southeast Asia has led to an increase in disposable income and healthcare spending, which has further boosted the demand for antiviral drugs. In addition, the region's large population and high population density make it particularly susceptible to viral outbreaks, which has also contributed to the growth of the antiviral drug market.Overall, the Antiviral Drugs market in Southeast Asia is expected to continue its growth trajectory in the coming years, driven by increasing healthcare awareness, government investment in healthcare infrastructure, and the ongoing threat of viral outbreaks. However, the prevalence of counterfeit drugs and other regulatory challenges will need to be addressed to ensure the continued growth and success of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
